Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) issued its earnings results on Wednesday. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.04, Bloomberg Earnings reports. During the same period last year, the firm earned ($0.15) earnings per share.

COPYRIGHT VIOLATION WARNING: “Achillion Pharmaceuticals, Inc. (ACHN) Releases Earnings Results, Beats Estimates By $0.04 EPS” was posted by American Banking News and is the property of of American Banking News. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at

Several analysts have recently commented on the company. BidaskClub raised Achillion Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, July 6th. Maxim Group set a $7.00 target price on Achillion Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Robert W. Baird cut Achillion Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $5.00 target price for the company. in a research report on Thursday, August 10th. Zacks Investment Research cut Achillion Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Finally, Chardan Capital reduced their price objective on Achillion Pharmaceuticals from $5.00 to $4.00 and set a “neutral” rating for the company in a research report on Wednesday, August 9th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $6.75.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.

Earnings History for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.